The assessment discusses fifty eight peptides in several clinical phases, indicating a sturdy pipeline of peptide therapies concentrating on PPIs.Clinical trials and preclinical studies are highlighted, demonstrating the efficacy of peptide vaccines in inducing an immune response, with the potential to further improve survival fees for HCC patients